Table 1.
Example of classification results in examples of electronic nose applications to lung cancer. The last two examples are concerned with the identification of the response to treatment; baseline is the status before treatment; partial response, stable diseases, and progressive diseases are the categories defined by the “Response Evaluation Criteria in Solid Tumors” (RECIST) approach [50].
| Case | Sensitivity | Specificity | Accuracy | Reference |
|---|---|---|---|---|
| Lung cancer vs. control | 100% | 90% | 93% | [43] |
| Lung cancer vs. control | 100% | 83% | 90% | [44] |
| Lung cancer vs control | 91.8% | 68.8% | 90.3% | [48] |
| Early LC vs benign nodule | 75% | 93.3% | 86.9% | [46] |
| EGFR vs. wild-type | 78.9% | 85.3% | 83.02% | [46] |
| Baseline vs. partial response and stable disease | 93% | 85% | 89% | [47] |
| partial response and stable disease vs. progressive disease | 28% | 100% | 92% | [47] |